Compare Stocks → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KRBPNASDAQ:PHIONASDAQ:SNESNASDAQ:STSS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRBPKiromic BioPharma$3.20-0.6%$2.78$0.16▼$4.08$4.93M1.982,067 shs602 shsPHIOPhio Pharmaceuticals$0.73-2.7%$0.73$0.50▼$4.10$3.35M1.36104,459 shs29,795 shsSNESSenesTech$0.75+2.7%$0.74$0.52▼$16.56$3.85M0.68186,491 shs33,658 shsSTSSSharps Technology$0.38-20.7%$0.30$0.17▼$1.05$5.99M1.1325.31 million shs19.07 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRBPKiromic BioPharma-0.62%0.00%+28.00%+35.59%+0.95%PHIOPhio Pharmaceuticals-2.94%-4.58%-3.76%-23.82%-79.14%SNESSenesTech+2.66%+6.90%-4.86%-15.89%-94.71%STSSSharps Technology-20.08%+78.25%+53.11%-0.75%-61.02%On June 10, Nvidia makes its next big move (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.3195 of 5 stars3.55.00.00.03.50.81.3SNESSenesTech1.641 of 5 stars3.52.00.00.02.10.01.3STSSSharps TechnologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRBPKiromic BioPharmaN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00447.95% UpsideSNESSenesTech3.00Buy$3.50367.04% UpsideSTSSSharps TechnologyN/AN/AN/AN/ACurrent Analyst RatingsLatest SNES, PHIO, KRBP, and STSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/14/2024SNESSenesTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50(Data available from 6/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRBPKiromic BioPharmaN/AN/AN/AN/A($4.68) per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.22 per shareN/ASNESSenesTech$1.19M3.24N/AN/A$0.90 per share0.83STSSSharps TechnologyN/AN/AN/AN/A$0.44 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRBPKiromic BioPharma-$20.95M-$9.90N/A∞N/AN/AN/A-133.33%N/APHIOPhio Pharmaceuticals-$10.83M-$3.25N/A0.19N/AN/A-123.19%-98.58%8/8/2024 (Estimated)SNESSenesTech-$7.71MN/A0.00N/AN/A-545.82%-181.46%-146.47%8/8/2024 (Estimated)STSSSharps Technology-$9.84MN/A0.00∞N/AN/A-102.25%-72.97%8/13/2024 (Estimated)Latest SNES, PHIO, KRBP, and STSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024STSSSharps TechnologyN/A-$0.05-$0.05-$0.05N/AN/A5/10/2024Q1 2024KRBPKiromic BioPharmaN/A-$1.00-$1.00-$1.00N/AN/A5/9/2024Q1 2024PHIOPhio PharmaceuticalsN/A-$0.47-$0.47-$0.47N/AN/A5/9/2024Q1 2024SNESSenesTech-$0.34-$0.36-$0.02-$0.36$0.43 million$0.42 million 4/1/2024Q4 2023PHIOPhio PharmaceuticalsN/A-$0.17-$0.17-$0.17N/AN/A3/29/2024Q4 2023STSSSharps TechnologyN/A-$0.16-$0.16-$0.16N/AN/A3/18/2024Q4 2023KRBPKiromic BioPharmaN/A-$4.16-$4.16-$4.16N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRBPKiromic BioPharmaN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ASNESSenesTechN/AN/AN/AN/AN/ASTSSSharps TechnologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRBPKiromic BioPharmaN/A0.290.29PHIOPhio PharmaceuticalsN/A5.485.48SNESSenesTech0.036.915.69STSSSharps TechnologyN/A1.150.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRBPKiromic BioPharma10.91%PHIOPhio Pharmaceuticals57.31%SNESSenesTech5.19%STSSSharps Technology17.17%Insider OwnershipCompanyInsider OwnershipKRBPKiromic BioPharma20.59%PHIOPhio Pharmaceuticals0.59%SNESSenesTech5.32%STSSSharps Technology14.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKRBPKiromic BioPharma351.54 million1.23 millionNot OptionablePHIOPhio Pharmaceuticals84.59 million4.57 millionNot OptionableSNESSenesTech255.14 million4.87 millionNot OptionableSTSSSharps Technology5715.67 million13.46 millionNot OptionableSNES, PHIO, KRBP, and STSS HeadlinesRecent News About These CompaniesMay 31 at 8:30 AM | globenewswire.comSharps Technology's SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.May 30 at 11:50 AM | marketbeat.com3 Penny Stocks Trading Abnormal Volume TodayMay 30 at 11:49 AM | marketbeat.com3 Penny Stocks Trading Abnormal Volume Today (STSS)May 30 at 8:30 AM | globenewswire.comSharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.May 28, 2024 | benzinga.comLatest News for Sharps Technology Stock (NASDAQ:STSS)May 28, 2024 | globenewswire.comSharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured SyringesMay 28, 2024 | benzinga.comUS Stocks Mixed; Home Prices Increase In MarchMay 28, 2024 | investorplace.comWhy Is Sharps Technology (STSS) Stock Up 194% Today?May 23, 2024 | yahoo.com'Sharp (and safe) knives': Grab a set of Henckels for $125 (a 65% price chop) — plus other incredible deals todayMay 22, 2024 | bovnews.comIs it possible to sustain this rally? Sharps Technology Inc (STSS) StockMay 14, 2024 | forbes.comSharp Alpha Raises $25 Million For Sports, Gaming And Entertainment FundMay 7, 2024 | tmcnet.comSharp Token Announces Launch on Coinstore ExchangeApril 27, 2024 | msn.comSharp plans $3-5 bn fab unit in IndiaApril 18, 2024 | msn.comSharp’s new compact soundbar delivers affordable Dolby AtmosApril 16, 2024 | yahoo.comSharp launches its first ever dual drawer air fryer, and the price will surprise youApril 11, 2024 | thevermilion.comSharp's 55 inch and Aquos's return to the future | ProofApril 2, 2024 | piworld.comSharp Now Shipping Digital Production PressesMarch 23, 2024 | latimes.comSonja SharpMarch 22, 2024 | tradewindsnews.comShipping lifer Sharp-Patel seeks to inspire the next generation of womenMarch 22, 2024 | digitimes.comSharp mulls cutting SDP loose, large-sized LCD lines at riskMarch 16, 2024 | stanfordreview.orgEXCLUSIVE: The Review Sits Down with President Richard SallerNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsKiromic BioPharmaNASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.SenesTechNASDAQ:SNESSenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.Sharps TechnologyNASDAQ:STSSSharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.